The book focuses on the negotiation process leading up to the creation of the Convention on Biodiversity (CBD) and the domestic implementation of this international agreement. This political science study of the negotiation process applies several perspectives drawn from international relations theories, while also focusing on the implementation of international environmental agreements in a developing country. Moreover, the links between factors at international and domestic levels are examined, with four proposed mechanisms through which an international institution may affect domestic policies. Evidence is found that the CBD has had a beneficial impact on national biodiversity policies in the country studied, but that necessary compatible legislation is absent in developed country parties. Readership: Policy makers, decision makers, political scientists, lawyers and environmentalists engaged in development assistance work, and academics and industrialists involved in the biotechnology industry.

Predictions about the success of the Convention on Biological Diversity (CBD) are pessimistic. It has now become commonplace to bemoan the scope, ambition, and deeply political nature of a convention that addresses issues ranging from ecosystems protection to the exploitation of genetic resources, from conservation to justice, and from commerce to scientific knowledge. Ten years after its adoption, how can we assess the difference that the CBD has made? Is it in danger of collapsing under its own weight or is it building the foundations of new patterns of relations between societies and nature? What achievements can we record and what challenges does it face? In this book, which is unique in its scope, diversity and the wealth of information it contains, contributors from a variety of academic disciplines tackle an issue of enduring importance to the protection of biodiversity and enhance our understanding of humanity's capacity to reconcile its various aspirations and halt the destructive path upon which it is set.

Demonstrating the shortcomings of current policy and legal approaches to access and benefit-sharing (ABS) in the Convention on Biological Diversity (CBD), this book recognizes that genetic resources are widely distributed across countries and that bilateral contracts undermine fairness and equity. The book offers a practical and feasible regulatory alternative to ensure the goal of fairness and equity is effectively and efficiently met. Through a legal analysis that also incorporates historic, economic and sociological perspectives, the book argues that genetic resources are not tangible resources but information. It shows that the existing preference for bilateralism and contracts reflects resistance on the part of many of the stakeholders involved in the CBD process to recognize them as such. ABS issues respond very well to the economics of information, yet as the author explains, these have been either sidelined or overlooked. At a time when the Nagoya Protocol on ABS has renewed interest in feasible policy options, the author provides a constructive and provocative critique. The institutional, policy and regulatory framework constitute "bounded openness" under which fairness and equity emerge.

INCOMPLETE.

The implications of biodiversity loss for the global environment have been widely discussed, but only recently has attention been paid to its direct and serious effects on human health. Biodiversity loss affects the spread of human diseases, causes a loss of medical models, diminishes the supplies of raw materials for drug discovery and biotechnology, and threatens food production and water quality. Biodiversity and Human Health brings together leading thinkers on the global environment and biomedicine to explore the human health consequences of the loss of biological diversity. Based on a two-day conference sponsored by the National Institutes of Health, the National Science Foundation, and the Smithsonian Institution, the book opens a dialogue among experts from the fields of public health, biology, epidemiology, botany, ecology, demography, and pharmacology on this vital but often neglected concern. Contributors discuss the uses and significance of biodiversity to the practice of medicine today, and develop strategies for conservation of these critical resources. Topics examined include: the causes and consequences of biodiversity loss emerging infectious diseases and the loss of biodiversity the significance and use of both prescription and herbal biodiversity-derived remedies indigenous and local peoples and their health care systems sustainable use of biodiversity for medicine an agenda for the future In addition to the editors, contributors include Anthony Artuso, Byron Bailey, Jensa Bell, Bhaswati Bhattacharya, Michael Boyd, Mary S. Campbell, Eric Chivian, Paul Cox, Gordon Cragg, Andrew Dobson, Kate Duffy-Mazan, Robert Engelman, Paul Epstein, Alexandra S. Fairfield, John Grupenhoff, Daniel Janzen, Catherine A. Laughin, Katy Moran, Robert McCaleb, Thomas Mays, David Newman, Charles Peters, Walter Reid, and John Vandermeer. The book provides a common framework for physicians and biomedical researchers who wish to learn more about environmental concerns, and for members of the environmental community who desire a greater understanding of biomedical issues.

This report sets the economic and business case for urgent and ambitious action on biodiversity. It presents a preliminary assessment of current biodiversity-related finance flows, and discusses the key data and indicator gaps that need to be addressed to underpin effective monitoring of both the pressures on biodiversity and the actions (i.e. responses) being implemented. The report concludes with ten priority areas where G7 and other countries can prioritise their efforts.